{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:00:42Z","timestamp":1789189242997,"version":"build-2803163510"},"reference-count":54,"publisher":"JLE","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.nephro.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T06:15:41Z","timestamp":1496297741000},"page":"S47-S53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"S1","title":["Renin\u2013angiotensin system blockade: Finerenone"],"prefix":"10.1684","volume":"13","author":[{"given":"Luis M.","family":"Ruilope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.02.003_bib0280","first-page":"e012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nuclear Receptor Signalling"},{"key":"10.1016\/j.nephro.2017.02.003_bib0285","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","article-title":"Aldosterone, mineralocorticoid receptor, and heart failure","volume":"350","author":"Messaoudi","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0290","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nephro.2017.02.003_bib0295","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcad.2009.12.003","article-title":"Aldosterone and mineralocorticoid receptors in the cardiovascular system","volume":"52","author":"Funder","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.nephro.2017.02.003_bib0300","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0305","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semnephrol.2014.04.005","article-title":"Comparison of agents that affect aldosterone action","volume":"34","author":"Tamargo","year":"2014","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0310","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","article-title":"Mineralocorticoids in the heart and vasculature: new insights for old hormones","volume":"55","author":"Lother","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanism of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"Fuller","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0320","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1210\/en.2013-1834","article-title":"Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action","volume":"155","author":"Coutinho","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.nephro.2017.02.003_bib0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2003.10.018","article-title":"A quick glance at rapid aldosterone action","volume":"217","author":"L\u00f6sel","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0330","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0735-1097(01)01539-X","article-title":"Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction","volume":"38","author":"Hayashi","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0335","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"Ivanes","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0340","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the emphasis-HF (eplerenone in mild patients hospitalization and survival study in heart failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0345","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1161\/CIRCULATIONAHA.106.670109","article-title":"Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death","volume":"115","author":"Pitt","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2017.02.003_bib0350","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2009-2521","article-title":"Aldosterone production and insulin resistance in healthy adults","volume":"95","author":"Garg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nephro.2017.02.003_bib0355","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2017.02.003_bib0360","doi-asserted-by":"crossref","first-page":"B27","DOI":"10.1093\/eurheartj\/sur009","article-title":"Physiology of aldosterone and pharmacology of aldosterone blockers","volume":"13","author":"Struthers","year":"2011","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.nephro.2017.02.003_bib0365","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2007-0030","article-title":"A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function","volume":"29","author":"Connell","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.nephro.2017.02.003_bib0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","article-title":"Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease","volume":"65","author":"Buglioni","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.nephro.2017.02.003_bib0375","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.nephro.2017.02.003_bib0380","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0385","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.nephro.2017.02.003_bib0390","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0395","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.coph.2012.12.007","article-title":"Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications","volume":"13","author":"Zwadlo","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0400","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IBPC.S13783","article-title":"Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine","volume":"6","author":"Funder","year":"2013","journal-title":"Integr Blood Press Control"},{"key":"10.1016\/j.nephro.2017.02.003_bib0405","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.nephro.2017.02.003_bib0410","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","article-title":"Role of mineralocorticoid receptor antagonists in cardiovascular disease","volume":"116","author":"Ferrario","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.nephro.2017.02.003_bib0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","article-title":"Aldosterone blockade in CKD: emphasis on pharmacology","volume":"22","author":"Schwenk","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nephro.2017.02.003_bib0420","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0425","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ncpendmet0676","article-title":"Drug insight: eplerenone, a mineralocorticoid-receptor antagonist","volume":"4","author":"McManus","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.nephro.2017.02.003_bib0430","first-page":"13851","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"Chem Med Chem"},{"key":"10.1016\/j.nephro.2017.02.003_bib0435","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nephro.2017.02.003_bib0440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0445","doi-asserted-by":"crossref","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","author":"Kolkhof","year":"2016","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0450","unstructured":"Ergueden JK, Kolkhof P, Sandner P, Kuhl A, Stasch JP, Pook E, Schlemmer KH. Int Pat Appl WO2005\/08774."},{"key":"10.1016\/j.nephro.2017.02.003_bib0460","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nephro.2017.02.003_bib0465","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.nephro.2017.02.003_bib0470","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number ofmarketed dihydropyridine calcium channel blockers havemineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.nephro.2017.02.003_bib0475","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.nephro.2017.02.003_bib0480","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/mol.51.2.285","article-title":"Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone","volume":"51","author":"Massaad","year":"1997","journal-title":"Mol Pharmacol"},{"issue":"Abstract Suppl","key":"10.1016\/j.nephro.2017.02.003_bib0485","first-page":"772","article-title":"Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure","volume":"33","author":"Delbeck","year":"2012","journal-title":"Eur Heart J"},{"issue":"Abstract Suppl","key":"10.1016\/j.nephro.2017.02.003_bib0490","first-page":"7","article-title":"Pronounced cardiac protection by BAY\u00a094-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure","volume":"32","author":"Albrecht-Kuepper","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0495","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.nephro.2017.02.003_bib0500","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","article-title":"Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction","volume":"67","author":"Gueret","year":"2016","journal-title":"Hypertension"},{"issue":"Abstract Supplement","key":"10.1016\/j.nephro.2017.02.003_bib0505","first-page":"829","article-title":"Finerenone improves diastolic function in a preclinical model of type\u00a02 diabetes mellitus","volume":"37","author":"Mulder","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0510","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone\u2013results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.nephro.2017.02.003_bib0515","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel Non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.nephro.2017.02.003_bib0520","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0525","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0530","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2017.02.003_bib0535","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.nephro.2017.02.003_bib0540","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type\u00a02 diabetes mellitus and diabetic nephropathy","author":"Katayama","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.nephro.2017.02.003_bib0545","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.003_bib0550","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.02.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:42:00Z","timestamp":1741192920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517300445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":54,"alternative-id":["S1769725517300445"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.02.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin\u2013angiotensin system blockade: Finerenone","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}